Drug Trial Radar · NCT07642050
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Sep 2028
Study completion Oct 2029
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
Conditions
- IgA Nephropathy
Interventions
BHV-1400Drug
500 mg delivered subcutaneously via autoinjector
PlaceboDrug
Matching placebo delivered subcutaneously via autoinjector
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in natural log-transformed Urine Protein to Creatinine Ratio (UPCR) at Week 52Time frame: Baseline to Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.